Fenoldopam and Ketanserin for Acute Kidney Failure Prevention After Cardiac Surgery
Status:
Terminated
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to compare the effect of fenoldopam and ketanserin on kidney
function preservation in patients at high risk for renal failure after cardiac surgery.
Acute, oliguric renal failure develops in up to 2% of patients undergoing cardiac surgery.
Some of them require renal replacement therapy and despite that mortality in this group
exceeds 30-60%. The investigators await that the use of fenoldopam and/or ketanserin may
decrease the rate of severe renal failure.